60 Degrees shares surge 71.81% intraday after trial shows tafenoquine cures all three babesiosis patients.

60 Degrees Pharmaceuticals surged 71.81% intraday after announcing that all three patients in its trial for relapsing babesiosis in immunosuppressed patients were cured using tafenoquine-based regimens. The data, combined with a 2024 Yale study showing 100% cure rates in seven patients, highlights tafenoquine’s potential to revolutionize treatment for this rare, life-threatening disease. The company emphasized the need for updated guidelines given the high efficacy, despite tafenoquine’s current FDA approval only for malaria prophylaxis. The breakthrough underscores the drug’s unmet medical need and future regulatory opportunities, driving investor optimism.